---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-389308"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-09-11T20:21:51+00:00"
generated_at: "2026-09-11T20:23:07.623886+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Artiva shareholders approve 5.1M share increase to 2024 equity plan at annual meeting

## Summary
- Stockholders approved amendment to 2024 Equity Incentive Plan adding 5,097,095 shares to Share Reserve.
- Vote on plan amendment: 32,527,133 for, 6,816,989 against, 22,759 abstentions, 4,640,922 broker non-votes.
- Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. elected for three-year terms through 2029.
- KPMG LLP ratified as independent auditor for FY2026: 44,000,762 for, 4,325 against, 2,716 abstentions.
- Amended plan also counts pre-funded warrant shares in annual automatic reserve increase (starting Jan 1, 2027).

## SEC filing metadata
- accession: 0001193125-26-389308
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-09-11T20:21:51+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/0001193125-26-389308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/artv-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-389308
- JSON: https://secwatch.observer/filing/0001193125-26-389308.json
- Plain text: https://secwatch.observer/filing/0001193125-26-389308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.